403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
CAR T-Cell Neurotoxicity Detection Market Overview And Strategic Developments By Towards Healthcare
(MENAFN- GlobeNewsWire - Nasdaq) This report, published by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the CAR T-cell neurotoxicity detection market. It explores key growth drivers, regional insights, and emerging innovations shaping the future of oncology diagnostics.
![]()
Ottawa, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The CAR T-cell neurotoxicity detection market
While North America currently leads the market, the Asia Pacific region is expected to experience the fastest expansion. The development of early detection tools and real-time monitoring systems is transforming clinical strategies for addressing CAR T-cell-related neurotoxicity.
This market's growth is largely fueled by the expanding use of CAR T-cell therapy, supported by the rising demand for personalized medicine advancement of the medical device sector The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @Key Takeaways
- North America held a major revenue share of 52.5% in the market in 2024. Asia-Pacific is expected to host the fastest-growing market in the coming years. By detection method, the biomarker-based detection segment contributed the biggest revenue share of approximately 37.6% in the CAR T-cell neurotoxicity detection market in 2024. By detection method, the AI-based & wearable monitoring segment is expected to grow at the highest CAGR between 2025 and 2034. By product/service type, the diagnostic kits & reagents segment held the largest revenue share of approximately 52.5% in 2024. By product/service type, the software & algorithms segment is expected to grow at the fastest CAGR over the projected period. By biomarker source, the blood-based biomarkers segment registered its dominance over the global market with a share of approximately 60% in 2024. By biomarker source, the cerebrospinal fluid (CSF) biomarkers segment is expected to witness the fastest growth in the CAR T-cell neurotoxicity detection market over the forecast period. By end-user, the cancer centres & hospitals segment held a dominant revenue share of 66.6% in the market in 2024. By end-user, the biotech & CAR-T developers segment is expanding at the fastest CAGR between 2025 and 2034. By indication, the B-cell malignancies segment led the global market with a share of 54.5% in 2024. By indication, the solid tumour CAR-T programs segment is expected to expand rapidly in the market in the coming years.
Market Overview & Potential
The market for CAR T-cell neurotoxicity detection encompasses the tools, technologies, and services designed to identify, track, and manage neurotoxic side effects especially ICANS (immune effector cell-associated neurotoxicity syndrome) in patients receiving CAR T-cell therapy. Neurotoxicity is among the most severe and potentially fatal adverse effects of CAR T-cells, emphasising the importance of early detection for patient safety and regulatory adherence. Detection methods include blood tests, MRI You can place an order or ask any questions, please feel free to contact us at ...What is the Growth Potential Responsible for the CAR T-Cell Neurotoxicity Detection Market?
The CAR T-cell neurotoxicity detection market is driven by the increasing adoption of CAR T-cell therapiesWhat Are the Growing Trends Associated with the CAR T-Cell Neurotoxicity Detection Market?
- Biomarker development: There is a significant focus on identifying and validating biomarkers (e.g., cytokine levels, CAR T-cell expansion kinetics) to predict and monitor neurotoxicity. Standardisation of methods: Researchers are working to standardise diagnostic techniques such as flow cytometry Early intervention and monitoring: The goal is to utilise early detection through these tools to implement timely interventions, such as corticosteroid Integration of advanced tools: The market is seeing an increased integration of advanced diagnostic tools into clinical practice. This includes both established methods, such as neurological exams, and newer technologies for real-time analysis. Focus on risk-benefit balance: As CAR T-cell therapies become more common, the market is focused on finding the right balance between therapeutic efficacy and the management of side effects like neurotoxicity.
What Is the Growing Challenge in the CAR T-Cell Neurotoxicity Detection Market?
The CAR T-cell neurotoxicity detection market faces challenges, including the need for faster, more sensitive, and standardised detection methods to monitor severe adverse events like immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS). Key challenges include the rapid and complex nature of these toxicities, a lack of universally standardised diagnostic tools, and difficulties in accurately differentiating between neurotoxicity and other conditions.
Regional Analysis
How Did North America Dominate the CAR T-Cell Neurotoxicity Detection Market in 2024?
North America held a major revenue share of 52.5% in the market in 2024. The North American CAR T-cell neurotoxicity detection market is a significant part of the larger CAR T-cell therapy market, driven by high demand for advanced cancer treatments, robust R&D, and supportive infrastructure. As CAR T-cell therapies become more widely adopted, the need for reliable detection and management of side effects like neurotoxicity is increasing. The market is being shaped by technological advancements in diagnostics and AI, along with regulatory support from agencies like the FDA, which have influenced the growth of the region's dominant position in the global CAR T-cell space.
Asia Pacific CAR T-Cell Neurotoxicity Detection Market Analysis:
The CAR T-cell neurotoxicity detection market in Asia Pacific (APAC) is an emerging sub-segment driven by the rapid growth of the broader CAR T-cell therapy market in the region, particularly in China, Japan, and South Korea. Key drivers include the increasing adoption of CAR T-cell therapies, advancements in gene editing technologies market focuses on developing biomarkers Get the latest insights on life science industry segmentation with our Annual Membership:Segmental Insights
By Detection Method,
The biomarker-based detection segment contributed the biggest revenue share of approximately 37.6% in the CAR T-cell neurotoxicity detection market in 2024. Biomarker-based detection methods play a key role in identifying early signs of neurotoxicity associated with CAR-T therapy. The approach supports clinical decision-making by allowing early intervention, reducing adverse events, and improving patient safety and therapy outcomes during CAR-T cell treatments.
The AI-based & wearable monitoring segment is expected to grow at the highest CAGR between 2025 and 2034. AI and wearable-based neurotoxicity monitoring solutions integrate real-time data analytics with physiological tracking to detect early neurological symptoms. These digital tools enhance monitoring accuracy, reduce dependence on invasive procedures, and facilitate proactive neurotoxicity management in CAR-T clinical settings.
By Product/Service Type,
The diagnostic kits & reagents segment held the largest revenue share of approximately 52.5% in 2024. Diagnostic kits and reagents enable laboratory-based detection of CAR-T-induced neurotoxicity by targeting specific biomarkers, cytokines, or immune-related proteins. Increasing demand for precision diagnostics and regulatory emphasis on patient safety
The software & algorithms segment is expected to grow at the fastest CAGR over the projected period. Software platforms and analytical algorithms serve as critical components for integrating patient data, biomarker analysis, and imaging results. They utilise machine learning to interpret complex datasets, identify neurotoxicity risk patterns, and guide treatment adjustments. Growing interest in AI-enabled clinical tools is expanding their use in predictive modelling and remote monitoring applications.
By Biomarker Source,
The blood-based biomarkers segment registered its dominance over the global market with a share of approximately 60% in 2024. Blood-based biomarkers such as cytokines, neurofilament light chains, and chemokines provide minimally invasive options for neurotoxicity assessment. This segment is favoured due to ease of sample collection, scalability for longitudinal monitoring, and compatibility with automated detection platforms.
The cerebrospinal fluid (CSF) biomarkers segment is expected to witness the fastest growth in the CAR T-cell neurotoxicity detection market over the forecast period. Cerebrospinal fluid (CSF) biomarkers offer a direct reflection of central nervous system pathology, making them valuable for severe neurotoxicity diagnosis. CSF-based assays detect neuroinflammatory markers and neuronal injury proteins that correlate with immune effector cell-associated neurotoxicity syndrome (ICANS). Despite being invasive, they deliver high diagnostic precision for complex neuroimmune events.
By End-User,
The cancer centres & hospitals segment held a dominant revenue share of 66.6% in the market in 2024. Cancer centres and hospitals represent the largest end-user segment, implementing neurotoxicity detection protocols alongside CAR-T treatment programs. They integrate biomarker assays, imaging, and digital monitoring within multidisciplinary clinical workflows. The increasing number of CAR-T therapy approvals and specialised oncology infrastructure support market growth in this categoryThe biotech & CAR-T developers segment is expanding at the fastest CAGR between 2025 and 2034. Biotech firms digital health companies
By Indication,
The B-cell malignancies segment led the global market with a share of 54.5% in 2024. Neurotoxicity detection solutions are widely used in CAR-T therapies targeting B-cell malignancies, such as leukaemia and lymphoma, where immune-related neurological side effects are common. Clinical trials and post-market monitoring continue to strengthen neurotoxicity risk stratification in this indication.
The solid tumour CAR-T programs segment is expected to expand rapidly in the market in the coming years. In solid tumour CAR-T applications, neurotoxicity monitoring is crucial due to emerging evidence of systemic immune activation. The growing development of CAR-T therapies for solid tumours increases demand for advanced neurotoxicity detection platforms.
Browse More Insights of Towards Healthcare:
The global CAR-T Cell Therapy Isolator market
The next-generation CAR-T therapy market
The in vivo CAR-T platform market
The multiple myeloma CAR-T market
The global autologous stem cell and non-stem cell therapies market
Recent Developments
- In March 2025, researchers from Kyushu University determined specific proteins associated with a damaging immune response that can affect the CNS after CAR T-cell therapy by analysing cerebrospinal fluid. Their study found that immunotherapy cancer treatment could be safer by helping healthcare professionals identify high-risk patients in advance. In June 2023, researchers in Germany and the U.S. found that a simple blood test identifying serum neurofilament light chain (NfL) can help detect the risk of developing ICANS following CAR T-cell therapy. NfL is a protein in the blood indicative of neuroaxonal injury, and its level increases, causing ICANS complications.
CAR T-Cell Neurotoxicity Detection Market Key Players List
- Diagnostic & Biotech Companies Thermo Fisher Scientific Bio-Techne (R&D Systems, ProteinSimple) Quanterix Corporation BD Biosciences Olink Proteomics Siemens Healthineers Roche Diagnostics PerkinElmer Merck KGaA (MilliporeSigma) Biognosys AG Neuromonitoring & Imaging Neuroelectrics GE Healthcare Natus Medical Compumedics Neuroscan Philips Healthcare AI, Software & Platform Developers Owkin Tempus AI CureMetrix Blackfynn (Neuroscience Data Integration) NeuroPace Inc.
Segments Covered in The Report
By Detection Method
- Biomarker-based Detection
- Cytokine levels (e.g. IL-6, IFN-γ, TNF-α) S100B, GFAP (glial damage markers) Neurofilament light chain (NfL) Endothelial markers (ANG2, VWF)
- Eye-tracking, reaction time apps Wearable EEG/neuromonitors
- MRI (contrast-enhanced) PET-CT
- EEG for seizure or encephalopathy detection
- Mini-Mental State Exam (MMSE) NIH Cognitive Test Battery
By Product/Service Type
- Diagnostic Kits & Reagents Software & Algorithms
- AI platforms for ICANS risk prediction
- EEG caps, wearable biosensors
By Biomarker Source
- Blood-based Biomarkers Cerebrospinal Fluid (CSF) Biomarkers Saliva/Plasma Proteomic Markers Neuroimaging Markers
By End-User
- Cancer Centers & Hospitals Biotech & CAR-T Developers Academic & Research Institutes Diagnostic Laboratories Clinical Trial Sponsors & CROs
By Indication
- B-cell Malignancies
- Diffuse Large B-cell Lymphoma (DLBCL) Acute Lymphoblastic Leukaemia (ALL)
By Region
- North America
- U.S. Canada
- China Japan India South Korea Thailand
- Germany UK France Italy Spain Sweden Denmark Norway
- Brazil Mexico Argentina
- South Africa UAE Saudi Arabia Kuwait
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
Comments
No comment